Distinguished in Peripheral T-Cell Lymphoma

Jun W. Zhu

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Distinguished in Peripheral T-Cell Lymphoma
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Jun Zhu practices in Beijing, China. Mr. Zhu is rated as a Distinguished expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 280 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 19 articles and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Gender
Male

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China
Other Locations
52 Fucheng Road, Haidian, 100142, China
100 Haining Road, Shanghai, 200080, China
No. 100 Haining Road, Shanghai, 200080, China
Haining Road 100, Shanghai, 200080, China
52 Fucheng Road, Beijing, 100142, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma
A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: SHR2554
Study Phase: Phase 1
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma
A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: April 03, 2024
Intervention Type: Biological
Study Drug: AK105
Study Phase: Phase 1/Phase 2
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell Lymphoma
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 1/Phase 2
Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1 ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma
Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1 ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 16, 2021
Intervention Type: Biological
Study Phase: Phase 1
Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma
Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: April 14, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Unknown
Publish Date: July 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 10 Less Clinical Trials

280 Total Publications

Influences of Commercial Dispersants on the Dyeing Performance and Dye-Fiber Interaction of Disperse Dyes in D5 Nonaqueous Medium Dyeing Systems.
Influences of Commercial Dispersants on the Dyeing Performance and Dye-Fiber Interaction of Disperse Dyes in D5 Nonaqueous Medium Dyeing Systems.
Journal: Langmuir : the ACS journal of surfaces and colloids
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Zhu's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 34 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile